OH2 oncolytic virus inhibits non-small-cell lung cancer metastasis via β-catenin pathway suppression

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Non-small-cell lung cancer (NSCLC) has poor survival rates, largely due to metastasis.
• Effective anti-metastatic therapies for NSCLC are urgently needed.

Purpose of the Study:

• To evaluate the anti-metastatic potential of the oncolytic virus OH2 in non-small-cell lung cancer (NSCLC).
• To elucidate the molecular mechanisms underlying OH2's anti-metastatic effects.

Main Methods:

• In vitro assays to assess NSCLC cell migration and invasion.
• In vivo lung metastasis model in mice.
• Analysis of beta-catenin mRNA and protein levels.
• Proteomic analysis of the cell secretome.
• Identification of viral proteins involved in the mechanism.

Main Results:

• OH2 significantly inhibited NSCLC cell migration and invasion in vitro and in a lung metastasis model.
• OH2 treatment led to downregulation of beta-catenin mRNA and protein.
• Reduced transcriptional activity of beta-catenin and downstream expression of Matrix Metalloproteinases (MMPs).
• Proteomic analysis confirmed decreased MMPs secretion after OH2 treatment.
• The OH2 tegument protein UL41 was identified as responsible for degrading beta-catenin mRNA.

Conclusions:

• The oncolytic virus OH2 exhibits potent anti-metastatic activity against NSCLC.
• OH2 disrupts the beta-catenin/MMPs signaling axis, inhibiting tumor invasion.
• The viral protein UL41 plays a key role in OH2's anti-metastatic mechanism by degrading beta-catenin mRNA.
• OH2 represents a promising therapeutic candidate for invasive NSCLC.